Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 16/20 | 0.54 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3341173 | 0.91 | NTRK1 (0.55) | NTRK1JAK2JAK3MKNK1MKNK2 | |
| SCHEMBL4152477 | 0.91 | NTRK1 (0.55) | NTRK1JAK2JAK3MKNK1MKNK2 | |
| SCHEMBL4151428 | 0.90 | NTRK1 (0.49) | NTRK1IGF1R | |
| SCHEMBL4159909 | 0.87 | NTRK1 (0.57) | NTRK1JAK2JAK3MKNK1MKNK2 | |
| SCHEMBL4073888 | 0.85 | NTRK1 (0.53) | NTRK1JAK2JAK3MKNK1MKNK2 | |
| SCHEMBL4071743 | 0.84 | NTRK1 (0.47) | NTRK1JAK2JAK3 | |
| SCHEMBL15209257 | 0.84 | PAK1 (0.53) | NTRK1IGF1R | |
| SCHEMBL4162039 | 0.82 | NTRK1 (0.62) | NTRK1JAK2JAK3IGF1R | |
| SCHEMBL4147398 | 0.82 | NTRK1 (0.52) | NTRK1JAK2JAK3IGF1R | |
| SCHEMBL4075878 | 0.82 | NTRK1 (0.49) | NTRK1JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005396-A1 | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005396-A1 | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain | P2RX3, DPYD, TYMP | NTRK1 3656/4885JAK2 1971/4885JAK3 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.